AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the...